AI Live: Scaling Artificial Intelligence Across Pharmaceuticals and Healthcare

The premier event for CAIOs, AI LIVE: The London Summit, is set to convene at Olympia, London, on 20–21 October 2026.

AI LIVE: The London Summit will unite over 2,000 global leaders under the theme 'Technology + Human Purpose' to examine the upcoming era of artificial intelligence.

Artificial intelligence is rapidly transforming healthcare and drug discovery. An article published by global pharmaceutical company Lundbeck highlights that one of the most significant applications of AI in drug discovery lies within medicinal chemistry.

By leveraging generative AI models, the company notes that computers can generate virtual small molecules, serving as inspiration for scientists to determine which compounds to synthesize. These molecules are engineered with specific properties in mind, offering the potential to become the next generation of promising drug candidates.

The AI systems learn from historical successes and failures, analyzing data on the measured properties of previously synthesized molecules to predict new virtual structures. Lundbeck emphasizes that this data-driven approach facilitates the generation of innovative ideas for molecules with enhanced properties.

At AI LIVE: The London Summit, this topic will be explored in depth by examining how AI is revolutionizing pharmaceutical research and development through accelerated scientific discovery, improved clinical trial success rates, and optimized drug development pipelines.

Taking place on 21 October at Olympia London, senior leaders from AstraZeneca, the NHS, and Lundbeck will discuss how AI is fundamentally transforming the industry.

Click here to secure your tickets to AI LIVE: The London Summit 2026.

AI LIVE: The London Summit will bring together more than 2,000 global leaders under the theme ‘Technology + Human Purpose’

Rapid AI advancements

AI's impact extends beyond small molecules; it is also revolutionizing the realm of biologics, according to Lundbeck. Biologics involve the study of large, complex molecules such as antibodies.

The company argues that AI-based protein structure predictions are changing the landscape, enabling researchers to understand the intricate 3D architecture of these molecules early in the biotherapeutic discovery process.

I’m thrilled to join the London AI Summit to discuss how biopharma is moving from AI experimentation to true enterprise transformation

Markus Kede, Chief AI Officer at Lundbeck

Advancements across life sciences and healthcare have been rapid on the frontier side. This week, Anthropic CEO Dario Amodei announced on X that Claude led the discovery of a molecular machine that the firm "suspects" could represent a new gene-editing mechanism.

The AI lab explains that Claude has discovered a previously unknown enzyme system hidden in the DNA of bacteriophages. Beside the enzyme’s gene sits a long array of repeating DNA – a structure that looks somewhat similar to CRISPR.

"Its precise function, biotechnological utility (if any), or level of significance is not yet clear, but at minimum it is work I would have been proud to do as a PhD student," Dario explained on X.

"The work was done mostly, though not entirely, by Claude: our life sciences team suggested a broad area of research, Claude read through the literature and a bunch of genome data and discovered something interesting, then Claude proposed experiments to verify the discovery and our team carried them out."

Some of the experts who will explore this topic in depth at BizClik's event include:

Markus Kede, Chief AI Officer at Lundbeck.

Markus Kede, Chief AI Officer at Lundbeck. Credit: Markus Kede/LinkedIn

Markus is responsible for setting Lundbeck’s enterprise AI direction and turning rapidly evolving AI capabilities into meaningful impact for patients and our business.

Markus says: "I’m thrilled to join the London AI Summit to discuss how biopharma is moving from AI experimentation to true enterprise transformation.

"Becoming a 'bionic company' isn't just about adopting technology; it’s about fusing AI, supercomputing and human neuroscience to compress discovery timelines from years to months and deliver life-changing therapies to patients faster."

He leads the enterprise AI strategy and transformation agenda, focused on embedding AI and bionic capabilities across the business to drive innovation, accelerate growth, improve productivity and create measurable value for patients, colleagues and stakeholders.

Tom Diethe, Executive Director, Head of the Centre for AI at AstraZeneca.

Tom Diethe, Executive Director, Head of the Centre for AI at AstraZeneca. Credit: Tom Diethe/LinkedIn

As Executive Director and Head of AstraZeneca's Centre for Artificial Intelligence, Tom leads a department of AI scientists and engineers working across multiple teams. His work spans target discovery, antibody design, in-silico lead optimisation, biomarker discovery, clinical trial optimisation and agentic AI for the full drug development pipeline.

Discussing the event, Tom says: "Excited to be part of the conversation as AI is moving fast to revolutionise drug discovery."

He has over 20 years of experience in applying ML and AI to solve tough problems with social impact.

Matea Deliu, Chief Clinical Information Officer at Bromley Healthcare / Guy's & St. Thomas's NHS Foundation Trust.

Matea Deliu, Chief Clinical Information Officer at Bromley Healthcare / Guy's & St. Thomas's NHS Foundation Trust. Credit: Matea Deliu/LinkedIn

Matea holds executive and senior clinical roles across NHS and commercial organisations. As Chief Clinical Information Officer at Bromley Healthcare, she leads digital strategy, clinical safety governance and data-led decision-making across community services.

At NHS South East London ICB, she leads digital delivery and GP IT strategy for primary care — shaping procurement decisions, responsible AI adoption and clinical system architecture across one of London's largest integrated care systems. She is the Primary Care Lead for the Responsible AI UK Health and Social Care Group, shaping national policy on AI governance in healthcare.

She is a Mentor for the NHS Innovation Accelerator and Expert in Residence at London Business School.

AI LIVE: The London Summit lands at Olympia

Staged on 20–21 October, AI LIVE: The London Summit promises to be the essential AI event of 2026.

Taking place at Olympia London, the inaugural conference and expo will bring together more than 2,000 global leaders shaping the future of AI under the theme Technology + Human Purpose.

Built for C-suite executives, AI strategists and senior innovators, the summit focuses on how AI moves from ambition to execution across the enterprise.

Attendees will gain practical, decision-ready insights into the technologies, frameworks and governance models defining the next era of AI.

Across two days, the agenda features:

• 50+ expert speakers sharing real-world use cases and strategic direction
• 10 focused content themes covering generative AI, automation, governance, digital identity and enterprise transformation
• Four executive-level workshops designed for hands-on learning and peer discussion
• Immersive AI Experience, a dedicated environment showing live demonstrations, interactive installations and applied AI in action.

This is where strategy meets reality, giving attendees a clear view of how AI is already reshaping industries.

Click here to secure your tickets to AI LIVE: The London Summit 2026.